EU IVDR Compliance Timeline 2026-2030: Data, Certification and Legacy Device Milestones

1. Key takeaways

Six milestones define the next five years for IVDR compliance: 2026-05-01 (start of the new EURL categories), 2026-05-28 (first four EUDAMED modules become mandatory), 2026-11-28 (end of the supplementary registration window for legacy devices under the 6-month staged rollout arrangement), 2027-02-25 (application of Implementing Regulation (EU) 2026/977), 2027-12-31, 2028-12-31 and 2029-12-31 (staged expiry of the legacy device route by class), and 2027-05-26 (UDI carrier requirement for Class A devices). Companies should schedule along three parallel lines, the data layer, the certification layer and the legacy device layer, with named owners for each milestone, because the deadlines interact: a missed EUDAMED registration blocks certificate work, and a missed legacy transition date removes the product from the market.

2. Legal basis

3. Expert insights

Insight 1: The data line (EUDAMED plus UDI) is the first to fall due.

Once the first four modules become mandatory on 2026-05-28, registration of new devices must be completed in EUDAMED, and legacy devices receive a 6-month supplementary registration window under the staged rollout arrangement. On UDI carriers, Class D devices have been subject since 2023-05-26, Class B and C devices since 2025-05-26, and Class A devices will be subject from 2027-05-26 (Article 113(3)(e)). The typical failure mode on this line is not a documentation gap but an actor who is not yet registered, which makes it impossible to submit any device or UDI data at all, so the actor registration step must precede everything else. Data readiness should therefore be treated as a gate condition for every downstream certification and legacy device milestone, not as a parallel administrative task that can slip.

Insight 2: The certification line (notified bodies plus EURL) sees two institutional changes in 2026 and 2027.

On 2026-05-01, the newly created EURL categories for markers of parasitic infection and blood group markers begin their Article 100(2) tasks, applying only to applications formally submitted from that date (Regulation (EU) 2025/2526). On 2027-02-25, Regulation (EU) 2026/977 applies, making quotations, time limits and annual reporting statutory obligations for notified bodies; for the first time, efficiency and fees between bodies become objectively comparable, which changes how manufacturers should select and manage their certification partners. Applications already in the pipeline should be checked against the cut-off: where the EURL category now applies and the application was submitted before the date, the new laboratory tasks should not be imposed retroactively.

Insight 3: The legacy device line is the only part with hard countdowns.

Transition qualification dates: QMS (2025-05-26, already passed), submission of the application (Class D 2025-05-26, Class C 2026-05-26, Class B and sterile Class A 2027-05-26), written agreement (Class D 2025-09-26, Class C 2026-09-26, Class B and sterile Class A 2027-09-26). Route endpoints: Class D 2027-12-31, Class C 2028-12-31, Class B and sterile Class A 2029-12-31. For Class C devices both relevant dates have already passed, and for Class B and sterile Class A devices only the two 2027 windows remain, which makes immediate assessment of feasibility indispensable for that cohort. Each of these dates is a hard deadline, not a target: missing the application or agreement date removes the device from the transition route entirely, so internal project dates should be set well ahead of the legal ones to leave room for notified body scheduling.

Insight 4: From 2027 to 2029, certificate expiries and re-certifications will peak.

As IVDR certificates reach their stated validity dates and legacy devices exit the market, notified body review resources will remain under sustained pressure in this period. Combined with the annual median fee and on-time completion rate data that bodies must publish from 2028 under Regulation (EU) 2026/977, companies should complete re-certification scheduling well before the validity date stated on the certificate; how far in advance is a practical estimate, and a lead time of at least 12 months is advisable. During the peak, bodies will also manage capacity through the interruption allowances permitted under Regulation (EU) 2026/977, so manufacturers who submit complete, well-structured applications will secure review slots earlier than those whose files need repeated completion rounds.

4. Practical recommendations

1. Build a three-line map covering the data line (EUDAMED / UDI), the certification line (notified bodies / EURL) and the legacy device line, marking each milestone with a named owner.
2. Prioritise the data line: obtain the SRN first, then schedule device and UDI data submission, and complete supplementary registration for legacy devices before 2026-11-28.
3. Rebuild certification scheduling on the time limit model of Regulation (EU) 2026/977, and include interruption scenarios in the plan.
4. For Class B and sterile Class A products, assess immediately whether the 2027-05-26 / 2027-09-26 windows can still be met.
5. Treat the progress of COM(2025) 1023 as an independent tracking item and make no early compliance investments based on it.

5. Verification checklist

• □ Marked: 2026-05-01 (new EURL categories), 2026-05-28 (EUDAMED mandatory), 2026-11-28 (legacy device supplementary registration)
• □ Marked: 2027-02-25 (application of Regulation (EU) 2026/977) and 2028-01-01 (annual reporting obligation)
• □ Marked: 2027-05-26 (UDI carriers for Class A devices)
• □ Marked legacy device staged expiry: D 2027-12-31, C 2028-12-31, B and sterile A 2029-12-31
• □ All three lines (data / certification / legacy) have named owners and schedules
• □ The progress of COM(2025) 1023 is tracked as an independent item

Legal information verified as of 29 October 2026.

GRZAN helps IVD manufacturers plan across the full IVDR compliance timeline: three-line milestone maps for data, certification and legacy device tracks, EUDAMED and UDI submission programmes, re-certification scheduling against notified body capacity, and monitoring of pending legislative changes. For support with timeline planning and implementation, contact info@grzanglobal.com.